Vandetanib - Nefrotox

Vandetanib

Marca

CAPRELSA
Clase

Inhibidores de la Proteinquinasa
Inhibidores no selectivos de Proteinquinasas
Indicación

Tiroides
Dosis

300 mg/d
Dosis renal

FG>60 dosis plena
FG 30-60: 200 mg/24 h
FG<30 CI
Comercializado en España

Si
▼ Nefrotoxicidad

HTA y Proteinuria. FRA mediado por la inhibición del transportador catiónico OCT2. Litiasis renal, Hiponatremia, hipopotasemia, hipomagnesemia, hipercalcemia. NIIA
▼ Plan

Ingesta hídrica elevada. Control analítico. De TA y clínico frecuente. Reposición iónica. Si NIIA corticoides.
TTº de la complicación que provoque según guías.
▼ Archivos

FICHA TÉCNICA - EMA - Vandetanib

IPT - AEMPS - Vandetanib

2013 - BR J CLIN PHARMACOL - Incidence and risk of hypertension with vandetanib in cancer patients - Systematic review

2020 - EXPERT REV CLIN PHARMACOL - Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials

2021 - INVEST NEW DRUGS - Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib

2021 - ONCOL REPORT - Dose adjustment for tyrosine kinase inhibitors in non‑small cell lung cancer patients with hepatic or renal function impairment

2021 - EUR J PHARM SCI - Inhibitory effects of vandetanib on creatinine transport via renal organic cation transporter OCT2

2021 - ENDOCRINE - Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer
Efectos indeseables de Anti VEFG